Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Groha

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The Lancet. Oncology|December 13, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker studyVivek Naranbhai, Mathias Viard, Michael Dean, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Nature Medicine|December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanomaChelsea A Taylor, Robert A Watson, Orion Tong, et al.
Cancer Cell|September 30, 2022
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitorsAmin H Nassar, Elio Adib, Sarah Abou Alaiwi, et al.
Nature Medicine|December 16, 2022
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Sarah Abou Alaiwi, Wenxin Xu, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Lancet. Oncology|December 13, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker studyVivek Naranbhai, Mathias Viard, Michael Dean, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Nature Medicine|December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanomaChelsea A Taylor, Robert A Watson, Orion Tong, et al.
Cancer Cell|September 30, 2022
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitorsAmin H Nassar, Elio Adib, Sarah Abou Alaiwi, et al.
Nature Medicine|December 16, 2022
Germline variants associated with toxicity to immune checkpoint blockadeStefan Groha, Sarah Abou Alaiwi, Wenxin Xu, et al.
Pageof 2